Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07147049
PHASE2

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.

Official title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

72

Start Date

2025-08-08

Completion Date

2026-01

Last Updated

2025-12-22

Healthy Volunteers

No

Interventions

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Locations (1)

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China